MedTrace Logo

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

NCT02163902 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2020-02-17

Study results available
· View outcomes & findings →

Summary

The investigation of the long-term safety and maintenance of efficacy of ATX-101 in reduction of submental fat.

Conditions

  • Submental Fat
  • Healthy

Interventions

DRUG

ATX-101

Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events

DRUG

Placebo

Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events

Sponsors & Collaborators

  • Kythera Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Frederick Beddingfield, III, MD, PhD · Sponsor GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-01-31
Completion
2016-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02163902 on ClinicalTrials.gov